Werewolf Therapeutics Receives Nasdaq Delisting Notice for Sub-$1.00 Stock Price

summarizeSummary

Werewolf Therapeutics, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  The company received a notice from Nasdaq on February 4, 2026, indicating non-compliance with the minimum $1.00 bid price rule, as its common stock traded below this threshold for 30 consecutive business days.

• 180-Day Compliance Period

  Werewolf Therapeutics has an initial 180 calendar days, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days.

• Potential for Further Extension

  If compliance is not met within the initial period, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market and meets other listing standards.

• Delisting Risk

  There is no assurance that the company will be able to regain compliance with the bid price requirement or avoid eventual delisting, which could severely impact its market access and investor appeal.

auto_awesomeAnalysis

Werewolf Therapeutics, Inc. has received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share. This notice, while not an immediate delisting, signals significant financial distress and a lack of investor confidence, especially following recent substantial share sales by a major investor, MPM BioVentures, as reported in January. The company now faces a critical 180-day period to regain compliance, which may require a reverse stock split or other measures to boost its share price. Failure to do so could lead to delisting, severely impacting its ability to raise capital and maintain liquidity, further complicating its already challenging financial position.